Sichuan Kelun-Biotech Biopharmaceutical Revises R&D Framework Agreement with Kelun Group

MT Newswires Live08-20

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has revised its existing Auxiliary R&D Services Framework Agreement with Sichuan Kelun Pharmaceutical (SHE:002422), a Monday filing with the Hong Kong Exchange said.

The revision includes expanded service scope, adjusted pricing, and increased annual caps for the years 2024 and 2025.

The company and Kelun Pharma had agreed to provide each party with auxiliary R&D services and equipment until Dec. 31, 2025. Given the requirements, the parties have agreed to extend the agreement.

Under the supplemental agreement, the company will pay 19 million yuan instead of 18 million yuan to Kelun Pharma group for the provision of services and equipment for 2024, and 17 million yuan instead of 15 million yuan for 2025.

The company will receive 17 million yuan instead of 16 million for 2024 from the remaining Kelun, and 18 million yuan instead of 16 million yuan for 2025.

Price (HKD): $168.30, Change: $-1.1, Percent Change: -0.65%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2460071124?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-20 18:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2460071124","market":"hk","top_or_hot":-1,"title":"Sichuan Kelun-Biotech Biopharmaceutical Revises R&D Framework Agreement with Kelun Group","media":"MT Newswires Live","content":"<html><body><p> Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has revised its existing Auxiliary R&amp;D Services Framework Agreement with Sichuan Kelun Pharmaceutical (SHE:002422), a Monday filing with the Hong Kong Exchange said.</p><p>The revision includes expanded service scope, adjusted pricing, and increased annual caps for the years 2024 and 2025.</p><p>The company and Kelun Pharma had agreed to provide each party with auxiliary R&amp;D services and equipment until Dec. 31, 2025. Given the requirements, the parties have agreed to extend the agreement.</p><p>Under the supplemental agreement, the company will pay 19 million yuan instead of 18 million yuan to Kelun Pharma group for the provision of services and equipment for 2024, and 17 million yuan instead of 15 million yuan for 2025.</p><p>The company will receive 17 million yuan instead of 16 million for 2024 from the remaining Kelun, and 18 million yuan instead of 16 million yuan for 2025.</p><p>Price (HKD): $168.30, Change: $-1.1, Percent Change: -0.65%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-Biotech Biopharmaceutical Revises R&D Framework Agreement with Kelun Group</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-Biotech Biopharmaceutical Revises R&D Framework Agreement with Kelun Group\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-20 18:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has revised its existing Auxiliary R&D Services Framework Agreement with Sichuan Kelun Pharmaceutical (SHE:002422), a Monday filing with the Hong ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0196878994.USD","symbol_name":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2460071124","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2460071124","pubTimestamp":1724151354,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical  has revised its existing Auxiliary R&D Services Framework Agreement with Sichuan Kelun Pharmaceutical , a Monday filing with the Hong Kong Exchange said.The revision includes expanded service scope, adjusted pricing, and increased annual caps for the years 2024 and 2025.The company and Kelun Pharma had agreed to provide each party with auxiliary R&D services and equipment until Dec. 31, 2025. Given the requirements, the parties have agreed to extend the agreement.Under the supplemental agreement, the company will pay 19 million yuan instead of 18 million yuan to Kelun Pharma group for the provision of services and equipment for 2024, and 17 million yuan instead of 15 million yuan for 2025.The company will receive 17 million yuan instead of 16 million for 2024 from the remaining Kelun, and 18 million yuan instead of 16 million yuan for 2025.Price : $168.30, Change: $-1.1, Percent Change: -0.65%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK1161":"生物科技","06990":"科伦博泰生物-B","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4023":"应用软件","BK4526":"热门中概股","HKD":"尚乘数科"},"translate_title":"四川科伦生物制药与科伦集团修订研发框架协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"06990":0.9},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has revised its existing Auxiliary R&D Services Framework Agreement with Sichuan Kelun Pharmaceutical (SHE:002422), a Monday filing with the Hong Kong Exchange said.The revision includes expanded service scope, adjusted pricing, and increased annual caps for the years 2024 and 2025.The company and Kelun Pharma had agreed to provide each party with auxiliary R&D services and equipment until Dec. 31, 2025. Given the requirements, the parties have agreed to extend the agreement.Under the supplemental agreement, the company will pay 19 million yuan instead of 18 million yuan to Kelun Pharma group for the provision of services and equipment for 2024, and 17 million yuan instead of 15 million yuan for 2025.The company will receive 17 million yuan instead of 16 million for 2024 from the remaining Kelun, and 18 million yuan instead of 16 million yuan for 2025.Price (HKD): $168.30, Change: $-1.1, Percent Change: -0.65%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460071124"}